MECHANISMS OF INTERACTION OF VIRAL CAUSATIVE AGENTS IN PATIENTS CO-INFECTED WITH HUMAN IMMUNODEFICIENCY AND HEPATITIS C VIRUSES

Cover Page


Cite item

Full Text

Abstract

In patients infected with human immunodeficiency virus (HIV) in 20 - 30% of cases co-infection with hepatitis C virus (HCV) is observed, that is associated with common routes of transmission for these causative agents. The main cause of lethal outcome for co-infected patients is liver damage. Thus, analysis of mechanisms of mutual influence of HIV and HCV under the conditions of co-infection gains special attention, that can be examined from both standpoints of direct inter-molecular interaction of 2 viral causative agents, as well as from the position of their immune-mediated effect. Negative effect of HIV on the course of fibrosis process in liver during HCVinfection is associated with the feature of this virus to cause deep alteration in the immune system by direct damage of CD4+ cells, disruption of mechanisms of immunological memory, suppression of functions of liver fraction of NK and NKT, as well as its ability of co-receptor interaction with hepatocytes and stellate cells, enhancing progress of fibrosis alterations and HCV replication in liver. HCV is also established to effect replication of HIV, stimulate infection of macrophages with this virus. All these events facilitate the rise in lethality during HIV and HCV co-infection.

About the authors

I. P. Balmasova

Russian University of Peoples’ Friendship; Evdokimov Moscow State Medical-Stomatological University

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

M. S. Aristanbekova

Evdokimov Moscow State Medical-Stomatological University; Saratov Regional Centre for Prophylaxis and Control of AIDS

Email: noemail@neicon.ru
Russian Federation

E. S. Malova

Russian University of Peoples’ Friendship

Email: noemail@neicon.ru
Russian Federation

R. I. Sepiashvili

Russian University of Peoples’ Friendship

Email: noemail@neicon.ru
Russian Federation

References

  1. Балмасова И.П., Ющук Н.Д., Сафиуллина Н.Х., Малова Е.С., Федосеева Н.В. Иммунофенотип и генотип в патогенезе и лечении хронического гепатита С. Российский иммунологический журнал. 2014, 8 (17): 772-775.
  2. Бикмухаметов Д.А. Гепатит С и ВИЧ-инфекция: профилактика, диагностика, лечение. М., Фонд развития межсекторного социального партнерства, 2010.
  3. Вышеславцева М.В., Балмасова И.П., Шестакова И.В. Иммунопатогенетические особенности коинфицирования вирусами иммунодефицита человека и гепатита С. Здоровье населения и среда обитания. 2015, 2 (263): 36-38.
  4. Малова Е.С., Ющук Н.Д., Балмасова И.П., Шмелева Е.В. CD56+ лимфоциты и иммунопатогенез хронического гепатита С. Иммунология. 2010, 31: 310-315.
  5. Покровский В.И., Жебрун А.Б. (ред.). Вирусные гепатиты в Российской Федерации. 8 выпуск. Санкт-Петербург, НИИЭМ им. Пастера, 2011.
  6. Сепиашвили Р.И. Физиология иммунной системы. М., Медицина - Здоровье, 2015.
  7. Сепиашвили Р.И., Балмасова И.П. Естественные киллеры и биогенные амины: паракринная регуляция в иммунной системе. Российский физиологический журнал им. И.М.Сеченова. 2005, 8: 927-932.
  8. Сепиашвили Р.И., Балмасова И.П. Иммунные синапсы: от теории к клинической практике. Молекулярная медицина.2008, 1: 14-22.
  9. Ярилин А.А. Иммунология. М., ЕЭОТАР-Медиа, 2010.
  10. Bailony M.R., Scherzer R., Huhn G. et al. Association of HIV infection, hepatitis C virus infection, and metabolic factors with liver stiffness measured by transient elastography. J. Infectious Diseases. 2013, 208: 1776-1783.
  11. Brenchley J.M., Price D.A., Schacker T.W. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine. 2006, 12: 1365-1371.
  12. Bruno R., Galastri S., Sacchi P. et al. gpl20 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut. 2010, 59: 513-520.
  13. Chen J.Y., Feeney E.R., Chung R.T. HCV and HIV co-infection: mechanisms and management. Nature Rev. Gastroenterology Hepatology. 2014, 11: 362-371.
  14. Corchado S., Lopez-Cortes L.F., Rivero-Juarez A. et al. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients. PLoS One. 2014, 9: el01760.
  15. Coppola N., Martini S., Pisaturo M., Sagnelli C. et al. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J. Virology. 2015, 4: 1-12.
  16. Gonzalez V.D., Landay A.L., Sandberg J.K. Innate immunity and chronic immune activation inHCV/HIV-1 co-infection. Clinical Immunology. 2010, 135: 12-25.
  17. Glassner A., Eisenhardt M., Kokordelis P. et al. Impaired CD4+ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J. Hepatology. 2013: 59: 427-433.
  18. Hernandez M.D., SermanK.E. HIV/HCVcoinfection natural history and disease progression, a review of the most recent literature. Current Opinion HIV AIDS. 2011, 6: 478-482.
  19. Hull M., Shafran S., Tseng A. et al. CIHR Canadian HIVtrials network co-infection and concurrent diseases core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Canadian J. Infectious Diseases Medical Microbiology. 2014, 25:311-320.
  20. Herbeuval J.P., Grivel J.C., Boasso A. et al. CD4 T-cell death induced by infectious and non-infectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood. 2005, 106: 3524-3531.
  21. Ingiliz R, Rockstroh J.K. Natural history of liver disease and effect of hepatitis C virus on HIV disease progression. Current Opinion HIV AIDS. 2015, 10: 303-308.
  22. Ivanov A.V., Bartosch B., Smirnova O.A. et al. HCV and oxidative stress in the liver. Viruses. 2013, 5: 439-469.
  23. Karageorgopoulos D.E., Allen J., Bhagani S. Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a «special population»? World J. Hepatology. 2015, 7:1936-1952.
  24. Kang L., Luo Z., Li Y. et al. Association of Vpu with hepatitis C virus NS3/4A stimulates transcription of type 1 human immunodeficiency virus. Virus Research. 2012, 163: 74-81.
  25. Krizhanovsky V, Yon M., Dickins R.A. et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008, 134: 657-667.
  26. Liberto M.C., Zicca E., Pavia G. et al. Virological mechanisms in the coinfection between HIV and HCV. Mediators Inflammation. 2015, 2015: 1-7.
  27. Loko M.A., Salmon D., Carrieri P. et al. The French national prospective cohort of patients coinfected with HIV and HCV(ANRS C013 HEPAVIH): early findings 2006 - 2010. BMC Infectious Diseases. 2010, 10: 303.
  28. Lopez-Dieguez M., Montes M.L., Pascual-Pareja J.F. et al. The natural history of liver cirrhosis in HIV/HCV coinfected patients. AIDS. 2011, 25: 899-904.
  29. Lin W., Tsai W. L., Shao R.X. et al. Hepatitis C virus regulates transforming growth factor beta 1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology. 2010, 138: 2509-2518.
  30. Marschalko M., Ponyai K., Karpati S. Sexually transmitted coinfections. HIV coinfections. OrvHetil. 2015, 156:4-9.
  31. Marcellin E, Roux R, Loko M.A. et al. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS C013 cohort. Clinical Infectious Diseases. 2014, 59: 1190-1192.
  32. Ming-Ju H., Yih-Shou H., Tzy-Yen C., Hui-Ling C. Hepatitis C virus E2 protein induce reactive oxygen species (ROS)-related fibrogenesis in the HSC-T6 hepatic stellate cell line. J. Cell Biochemistry. 2011, 112: 233-243.
  33. Mastroianni C.M., Lichtner M., Mascia C. et al. Molecular mechanisms of liver fibrosis in HIV/HCVcoinfection. International J. Molecular Sciences. 2014, 15: 9184-9208.
  34. Peng M., Xiao X., He Y. et al. HIV Vpr protein upregulates microRNA-122 expression and stimulates hepatitis C virus replication. J. General Virology. 2015, 96: 2453-2463.
  35. Rohrbach J., Robinson N., Harcourt G. et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut. 2010, 59: 1252-1258.
  36. Sherman K.E., Thomas D.L., Chung R.T. Human immunodeficiency virus and liver disease forum 2010: conference proceedings. Hepatology. 2011, 54: 2245-2253.
  37. Smith C., Sabin C.A., Lundgren J.D. et al. AIDS. 2010, 24: 1537-1548.
  38. Sagnelli C., Uberti-Foppa C., Galli L. Brazilian J. Infectious Diseases. 2014, 18: 164-169.
  39. Sagnelli C., Uberti-Foppa C., Pasquale G. et al. Factors influencing liver fibrosis and necroin-flammation in HIV/HCV coinfection and HCV monoinfection. Infection. 2013, 41: 959-967.
  40. Sajadi M.M., Shaken N., Talwani R., Redfield R.R. Hepatitis C infection in HIV-1 natural viral suppressors. AIDS. 2010, 24: 1689-1695.
  41. Sengupta S., Powell E., Kong L., Blackard J.T. Effects of HCV on basal and Tat-induced HIV LTR activation. PLoS ONE. 2013, 8: e64956.
  42. Sharma S.D. Hepatitis C virus: molecular biology and current therapeutic options. Indian Journal Medical Research. 2010, 131: 17-34.
  43. Simmonds P. The origin of hepatitis C virus. Current Topics Microbiology Immunology. 2013, 369: 1-15.
  44. Swaminathan G., Pascual D., Rival G. et al. Hepatitis C virus core protein enhances HIV-1 replication in human macrophages through TLR2, JNK, and MEKl/2-dependent upregulation of TNF-a and IL-6. FEBS Letters. 2014, 588: 3501-3510.
  45. Szereday L., Meggyes M., Halasz M. et al. Immunological changes in different patient populations with chronic hepatitis C virus infection. World J. Gastroenterology. 2016, 22: 4848-4859.
  46. Tsiara C.G., Nikolopoulos G.K., Dimou N.L. et al. Effect of hepatitis C virus on immunological and virological responses in HIV-infected patients initiating highly active antiretroviral therapy: a meta-analysis. J. Viral Hepatology. 2013, 20: 715-724.
  47. Wandeler G., Gsponer T, Bregenzer A. et al. Hepatitis C virus infections in the swiss HIV Cohort Study: a rapidly evolving epidemic. Clinical Infectious Diseases. 2012, 55: 1408-1416. *
  48. Witt M.D., Seaberg E.C., DarilayA. et al. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clinical Infectious Diseases. 2013, 57: 77-84.
  49. Yang D.R., Zhu H.Z. Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war? World J. Gastroenterology. 2015, 21: 3786-3800.
  50. Yoon C.H., Kim S.Y., Byeon S.E. et al. p53-derived host restriction of HIV-1 replication by protein kinase R-mediated tat phosphorylation and inactivation. J. Virology. 2015, 89: 4262-4280.
  51. Kong L., Cardona Maya W., Moreno-Femandez M.E. et al. Low-level HIVinfection ofhepa-tocytes. Virology J. 2012, 9: 157.
  52. perskalski E.A., Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Current HIV/AIDS Reports. 2011, 8: 12-22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Balmasova I.P., Aristanbekova M.S., Malova E.S., Sepiashvili R.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies